Grau-Sepulveda.

Shaw, Ph.D., Charles McKay, M.D., Laura L. Ritzenthaler, M.B.A., Jeffrey J. Popma, M.D., John C. Messenger, M.D., David M. Shahian, M.D., Frederick L. Grover, M.D., John E. Mayer, M.D., Cynthia M. Shewan, Ph.D., Kirk N. Garratt, M.D., Issam D. Moussa, M.D., George D. Dangas, M.D., and Fred H. Edwards, M.D.: Comparative Performance of Revascularization Strategies The strategies of percutaneous coronary intervention and coronary-artery bypass grafting for revascularization have been compared in randomized clinical trials.1,2 Although the ultimate way to control for treatment-selection bias is to carry out a randomized trial, such trials have limited power to evaluate subgroups often, and the results may not be generalizable, since sufferers and centers tend to be selected highly.No-one who is not really listed as an author contributed to the manuscript. Patients Patients were necessary to have differentiated thyroid carcinoma of follicular-cell origin, or its respective variants, confirmed in the MSKCC histopathologically. Thyrotropin alfa was provided by Genzyme, and selumetinib was supplied by AstraZeneca. IBA Molecular supplied the iodine-124 for the study. These ongoing companies didn’t participate in any facet of the study design, data accrual, data evaluation, or manuscript planning. The investigational new drug application for selumetinib was held by MSKCC.